Pharmaceutical - Financial, Anti-Arthritics/Rheumatics

Filter

Popular Filters

New treatment funded for severe gout in New Zealand

21-05-2014

Patients with severe gout will soon have a new treatment option as New Zealand’s Pharmaceutical Management…

AdenuricAnti-Arthritics/RheumaticsfebuxostatFinancialMenariniNew ZealandPharmaceuticalRegulation

NIH in $235 million partnership for lupus and other complex disease treatments

NIH in $235 million partnership for lupus and other complex disease treatments

05-02-2014

In the USA, the Lupus Foundation of America says that it will partner with the Foundation for the National…

Anti-Arthritics/RheumaticsFinancialPharmaceuticalResearch

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

DMC clears Merck & Co’s Alzheimer’s drug MK-8931 development

10-12-2013

The development program for MK-8931, a novel investigational oral beta-amyloid precursor protein site-cleaving…

Anti-Arthritics/RheumaticsFinancialFosamaxMerck & CoMK-8931NeurologicalNorth AmericaPharmaceuticalResearch

Karo Bio gets first milestone in Pfizer collaboration

06-09-2013

Under its collaboration with US pharma behemoth Pfizer (NYSE: PFE), Sweden's Karo Bio (STO: KARO) says…

Anti-Arthritics/RheumaticsDermatologicalsFinancialKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

Galapagos and Servier celebrate late stage discovery milestone

24-07-2013

Belgium-based Galapagos (Euronext: GLPG) has announced a late stage discovery milestone for small molecules…

Anti-Arthritics/RheumaticsBiotechnologyEuropeFinancialGalapagosPharmaceuticalServier

GlaxoSmithKline buys rights to MorphoSys RA drug candidate for up to $577 million

04-06-2013

German biotech firm MorphoSys (FSE: MOR) yesterday (June 3) saw its shares leap as much as 6%, as it…

Anti-Arthritics/RheumaticsFinancialLicensingPharmaceutical

Specialty drug costs account for over 50% of the total cost of care for RA and hepatitis C patients in USA

03-04-2013

According to two new studies by Prime Therapeutics, a leading US pharmacy benefit manager, rheumatoid…

Anti-Arthritics/RheumaticsAnti-viralsBiotechnologyFinancialHealthcareNorth AmericaPharmaceutical

US Judge imposes nearly $322 million fine on Merck & Co for illegal marketing

20-04-2012

US drug giant Merck & Co (NYSE: MRK) was sentenced by US District Court Judge Patti Saris in Boston to…

Anti-Arthritics/RheumaticsFinancialLegalMerck & CoNorth AmericaPharmaceuticalVioxx

Milestone for ChemoCentryx as GSK exercises license option

06-01-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) has exercised its option to obtain an exclusive license for…

Anti-Arthritics/RheumaticsChemoCentryxFinancialGlaxoSmithKlineLicensingPharmaceutical

Skyepharma updates on Exparel, Flutiform and financial position

14-11-2011

UK drug developer SkyePharma (LSE: SKP) yesterday issued an update on its R&D pipeline and provided an…

Anti-Arthritics/RheumaticsExparelFinancialFlutiformLodotraPharmaceuticalRegulationResearchRespiratory and PulmonarySkyepharma

Merck & Co highlights pipeline progress; plans eight US filings in 2012-

11-11-2011

US pharma giant Merck & Co (NYSE:MRK) hosted an upbeat R&D and Business Briefing yesterday, where it…

Anti-Arthritics/RheumaticsBridonCardio-vascularFinancialMerck & CoNeurologicalodanacatibOncologyPharmaceuticalRegulationResearchsuvorexantTredaptive

Back to top